EXPONENT INC·4

Apr 16, 5:18 PM ET

Corrigan Catherine 4

4 · EXPONENT INC · Filed Apr 16, 2026

Research Summary

AI-generated summary of this filing

Updated

Exponent (EXPO) CEO Catherine Corrigan Exercises Options, Sells Shares

What Happened
Catherine Corrigan, President & CEO and a director of Exponent (EXPO), exercised stock options and sold a portion of the resulting shares on March 16, 2026 and April 15, 2026. She exercised a total of 11,211 option shares (3,226 + 2,380 on 3/16; 3,225 + 2,380 on 4/15) at exercise prices of $25.41 (3,226/3,225 shares) and $29.05 (2,380 shares each date), incurring aggregate exercise costs of about $302,166. On the same dates she sold a total of 7,821 shares (3,912 on 3/16 and 3,909 on 4/15) in open-market transactions at prices of $67.49 and $67.70, generating combined proceeds of approximately $528,639. The sequence — option exercise followed by sales on the same days — is consistent with a cashless exercise where some exercised shares are immediately sold to cover costs/taxes.

Key Details

  • Dates and prices:
    • 2026-03-16: Exercised 3,226 @ $25.41 and 2,380 @ $29.05; sold 2,214 @ $67.49 and 1,698 @ $67.49.
    • 2026-04-15: Exercised 3,225 @ $25.41 and 2,380 @ $29.05; sold 2,212 @ $67.70 and 1,697 @ $67.70.
  • Totals: 11,211 shares exercised; 7,821 shares sold for ≈ $528,639; total exercise cost ≈ $302,166.
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Footnotes: F1 notes the option vests in four equal annual installments; F2 marked not applicable.
  • Timeliness: The March 16 transactions were reported in a Form 4 filed on 2026-04-16 (appears late relative to the two-business-day reporting rule); the April 15 trades were reported on 2026-04-16 (within reporting window).

Context

  • These filings show option exercises (derivative transactions) followed by open-market sales of shares — commonly a cashless exercise pattern used to cover exercise costs and taxes. Exercises are informative (management converting options into shares), while routine sales after exercise do not necessarily signal a change in view of the company.
  • The filing does not provide additional plans (e.g., a 10b5‑1 plan) or indicate gift/tax‑withholding codes beyond the standard exercise and sale entries.

Insider Transaction Report

Form 4
Period: 2026-03-16
Corrigan Catherine
DirectorChief Executive Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2026-03-16$25.41/sh+3,226$81,957104,195 total
  • Sale

    Common Stock

    2026-03-16$67.49/sh2,214$149,419101,981 total
  • Exercise/Conversion

    Common Stock

    2026-03-16$29.05/sh+2,380$69,139104,361 total
  • Sale

    Common Stock

    2026-03-16$67.49/sh1,698$114,595102,663 total
  • Exercise/Conversion

    Common Stock

    2026-04-15$25.41/sh+3,225$81,931105,888 total
  • Sale

    Common Stock

    2026-04-15$67.70/sh2,212$149,744103,676 total
  • Exercise/Conversion

    Common Stock

    2026-04-15$29.05/sh+2,380$69,139106,056 total
  • Sale

    Common Stock

    2026-04-15$67.70/sh1,697$114,881104,359 total
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    [F2][F1]
    2026-03-163,2269,676 total
    Exercise: $25.41Exp: 2026-07-29Common Stock (3,226 underlying)
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    [F2][F1]
    2026-04-153,2256,451 total
    Exercise: $25.41Exp: 2026-07-29Common Stock (3,225 underlying)
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    [F2][F1]
    2026-03-162,38011,898 total
    Exercise: $29.05Exp: 2027-02-16Common Stock (2,380 underlying)
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    [F2][F1]
    2026-04-152,3809,518 total
    Exercise: $29.05Exp: 2027-02-16Common Stock (2,380 underlying)
Footnotes (2)
  • [F1]The stock option becomes exercisable in four equal annual installments.
  • [F2]Not applicable.
Signature
By: Wendy Whitehouse For: Catherine Corrigan|2026-04-16

Documents

1 file
  • 4
    edgardoc.xmlPrimary

    PRIMARY DOCUMENT